Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News GSK American Depositary Shares Representing 2 Ordinary Shares GSK

Consumer Cyclical
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:GSK)

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

GlobeNewswire 4 days ago

New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

Business Wire October 24, 2024

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

Business Wire October 8, 2024

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

GlobeNewswire September 19, 2024

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

Business Wire September 18, 2024

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

GlobeNewswire August 6, 2024

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

Business Wire August 1, 2024

GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season

Business Wire July 11, 2024

US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

Business Wire June 7, 2024
View More News ››

Opinion & Analysis (NYSE:GSK)

Opportunities in cancer immunotherapy throttle up: George Zavoico of JonesTrading

George S. Mack June 25, 2015

Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

Benzinga.com  April 22, 2014

Everyone gets the flu

Marc Lichtenfeld March 6, 2013

Cash in on the growing Chinese pharmaceutical market

Tony D'Altorio September 10, 2010

Big Pharma has a big problem and merger mania is heating up

Marc Lichtenfeld July 29, 2010

Stock market myth: share buybacks work

Andrew Mickey October 29, 2008
View More Opinion ››

Bullboard Posts (NYSE:GSK)

Myriad Genetics Reports Strong Second Quarter 2024 Financial

News; $GSK Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises...
whytestocks - August 6, 2024

Great News !!!! this would be amazing !!

https://www.washingtonpost.com/health/2022/06/08/cancer-drug-trial/ https://nationalpost.com/health/small-cancer-drug-trial-sees...
Thunde - June 9, 2022

Glaxo

Doesn't sell the cure Glaxo Sells the disease
Rainbowflier - May 4, 2022

5% divided with huge upside with split

This company will be more profitable once they split up work it as two companies. Their pipeline of drugs and monoclonal antibody...
CBalardo - October 20, 2021

Bonvoyage12....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020

Why is it so low

I don't understand why this stock is even lower than before the pandemic. They have the potential to enter in the Covid vaccine...
IamMagic - December 1, 2020
View more Bullboard ››

Africa Oil Corp.

Africa Oil Corp.

Africa Oil Corp. is a Canadian oil and gas company with producing and development assets in deepwater Nigeria, an interest in ...
View More »